Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.

Frontiers in bioscience : a journal and virtual library - 1 Jan 2008

Yonemitsu Yoshikazu, Ueda Yasuji, Kinoh Hiroaki, Hasegawa Mamoru

Abstract excerpt

The utility of recombinant Sendai virus (rSeV) has been considerably examined over the last decade as a potent gene transfer candidate in a cytoplasmic gene expression system. Such risks as excessive immune responses associated with this virus administration in vivo however have limited its applicability in clinical settings as is the case with other viral vectors including adenoviruses. In consequence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dendritic Cells
Share to Gene Transfer Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Immunotherapy

Share to Neoplasms

Share to Sendai virus

Share to Tretinoin

Source

Identifiers

PMID: 17981677
DOI: 10.2741/2809

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen.PMID 17981677Read ↗

RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer.Semantic proximity Read ↗

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?Semantic proximity Read ↗

Recombinant Viruses for Cancer TherapySemantic proximity Read ↗

Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapySemantic proximity Read ↗

Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer TherapiesSemantic proximity Read ↗

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.Semantic proximity Read ↗

A cancer immunotherapy modality based on dendritic cell reprogramming <i>in vivo</i>Semantic proximity Read ↗

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virusSemantic proximity Read ↗

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerSemantic proximity Read ↗

Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development DirectionsSemantic proximity Read ↗

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapySemantic proximity Read ↗

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.